These include established activating FGFR mutations, FGFR1 N546K and K656E in low-grade (LGG) and high-grade glioma (HGG), neuroblastoma, medulloblastoma, glioblastoma, and Wilms tumour, and FGFR4 N535K/D and V550L/E in RMS [11, 12, 41, 42, 49, 54–57]. This evidence concerns the gene FGFR1 and central nervous system cancer.